Concepedia

The BioSTAR(r) device versus the CardioSEAL(r) device in patent foramen ovale closure: comparison of mid-term efficacy and safety

Ben J. Van den Branden, Justin Luermans, Martijn C. Post, H. W. M. Plokker, Jurriën M. ten Berg, Maarten J. Suttorp

EuroIntervention · 2010 · 23 citations · 28 references

DOI

Abstract

There is no difference in safety and efficacy at six months between the CardioSEAL(r) and BioSTAR(r) device used for PFO closure. However, using the BioSTAR(r) device tends to be associated with a higher percentage of moderate shunting.

References

28

Prevalence of Patent Foramen Ovale in Patients with Stroke

P Lechat, Jean‐Louis Mas, G Lascault et al. · New England Journal of Medicine · 1988 · 1.7K citations

, , +17

Recurrent Cerebrovascular Events Associated with Patent Foramen Ovale, Atrial Septal Aneurysm, or Both

Jean‐Louis Mas, Caroline Arquizan, Catherine Lamy et al. · New England Journal of Medicine · 2001 · 1.4K citations · Full text

Effect of Medical Treatment in Stroke Patients With Patent Foramen Ovale

Shunichi Homma, Ralph L. Sacco, Marco R. Di Tullio et al. · Circulation · 2002 · 943 citations · Full text

PATENT FORAMEN OVALE IN YOUNG STROKE PATIENTS

Mark Webster, H. Smith, D. N. Sharpe et al. · The Lancet · 1988 · 826 citations

, , +6

Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography.

Laure Cabanes, Jean‐Louis Mas, A. Cohen et al. · Stroke · 1993 · 573 citations